JP2019517549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517549A5 JP2019517549A5 JP2018564296A JP2018564296A JP2019517549A5 JP 2019517549 A5 JP2019517549 A5 JP 2019517549A5 JP 2018564296 A JP2018564296 A JP 2018564296A JP 2018564296 A JP2018564296 A JP 2018564296A JP 2019517549 A5 JP2019517549 A5 JP 2019517549A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348720P | 2016-06-10 | 2016-06-10 | |
| US62/348,720 | 2016-06-10 | ||
| PCT/IB2017/053405 WO2017212442A1 (en) | 2016-06-10 | 2017-06-08 | Therapeutic uses of a c-raf inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517549A JP2019517549A (ja) | 2019-06-24 |
| JP2019517549A5 true JP2019517549A5 (enExample) | 2020-07-16 |
Family
ID=59215827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564296A Pending JP2019517549A (ja) | 2016-06-10 | 2017-06-08 | Ｃ−ｒａｆ阻害薬の治療的使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190175609A1 (enExample) |
| EP (1) | EP3468595A1 (enExample) |
| JP (1) | JP2019517549A (enExample) |
| KR (1) | KR20190017767A (enExample) |
| CN (1) | CN109310761A (enExample) |
| AU (1) | AU2017279046B2 (enExample) |
| BR (1) | BR112018075371A2 (enExample) |
| CA (1) | CA3026876A1 (enExample) |
| CL (1) | CL2018003530A1 (enExample) |
| IL (1) | IL262961A (enExample) |
| MX (1) | MX2018015353A (enExample) |
| RU (1) | RU2018146886A (enExample) |
| WO (1) | WO2017212442A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3515446B1 (en) * | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| US11266653B2 (en) | 2017-05-02 | 2022-03-08 | Novartis Ag | Combination therapy |
| US10945904B2 (en) | 2019-03-08 | 2021-03-16 | Auris Health, Inc. | Tilt mechanisms for medical systems and applications |
| ES3025633T3 (en) | 2019-05-13 | 2025-06-09 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| BR112022007612A2 (pt) | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
| EP4071146A4 (en) * | 2019-12-06 | 2023-01-04 | Medshine Discovery Inc. | BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR |
| CN113912591B (zh) * | 2020-07-08 | 2023-10-20 | 齐鲁制药有限公司 | 联芳基化合物 |
| CN117425650A (zh) * | 2021-06-04 | 2024-01-19 | 齐鲁制药有限公司 | 一种raf激酶抑制剂的晶型及其制备方法 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| SI3102605T1 (sl) * | 2014-02-04 | 2019-04-30 | Pfizer Inc. | Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka |
| MX2017000546A (es) * | 2014-07-15 | 2017-03-08 | Genentech Inc | Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek. |
-
2017
- 2017-06-08 CA CA3026876A patent/CA3026876A1/en not_active Abandoned
- 2017-06-08 KR KR1020187035219A patent/KR20190017767A/ko not_active Ceased
- 2017-06-08 RU RU2018146886A patent/RU2018146886A/ru not_active Application Discontinuation
- 2017-06-08 JP JP2018564296A patent/JP2019517549A/ja active Pending
- 2017-06-08 BR BR112018075371-8A patent/BR112018075371A2/pt not_active Application Discontinuation
- 2017-06-08 CN CN201780035192.1A patent/CN109310761A/zh active Pending
- 2017-06-08 WO PCT/IB2017/053405 patent/WO2017212442A1/en not_active Ceased
- 2017-06-08 US US16/307,920 patent/US20190175609A1/en not_active Abandoned
- 2017-06-08 EP EP17733028.9A patent/EP3468595A1/en not_active Withdrawn
- 2017-06-08 AU AU2017279046A patent/AU2017279046B2/en not_active Ceased
- 2017-06-08 MX MX2018015353A patent/MX2018015353A/es unknown
-
2018
- 2018-11-12 IL IL262961A patent/IL262961A/en unknown
- 2018-12-07 CL CL2018003530A patent/CL2018003530A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| TWI764943B (zh) | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 | |
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| CA2856646C (en) | Combination treatment of cancer | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| CN106414493A (zh) | 包含突变的ras肽和化疗剂的肽疫苗 | |
| JP2021520406A5 (enExample) | ||
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| JP2023542093A (ja) | 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 | |
| JP2015500822A5 (enExample) | ||
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN104203232A (zh) | 用于抗肿瘤试剂施用的方法 | |
| JP2018531278A (ja) | 癌のための併用療法 | |
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| JP2021518348A5 (enExample) | ||
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| JP2023531090A5 (enExample) | ||
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| JP6549107B2 (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| TW201306833A (zh) | 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合 |